Atrial Fibrillation/Flutter in Transthyretin Cardiac Amyloidosis
JACC: Advances · 2026-02 · 5 (2) · 102470
DOI: 10.1016/j.jacadv.2025.102470 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Advances, 2026-02. Verfasst von Nicholas Chan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York Presbyterian…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Atrial fibrillation/flutter (AF) is common in transthyretin cardiac amyloidosis (ATTR-CA). The CHARGE-AF score has not been validated in ATTR-CA. The Columbia staging system is prognostic for survival, but its utility in predicting incident AF is unknown. OBJECTIVES: The authors aim to determine the predictors of prevalence and incidence of AF and the effect of tafamidis. METHODS: This is a retrospective cohort study of 419 patients with ATTR-CA. AF was ascertained from review of electrocardiograms, extended rhythm, device interrogations, and charted history. Binary logistic regression assessed for factors associated with prevalent AF. Cox regression time-to-event analysis assessed for factors associated with incident AF. RESULTS: AF was present in 58% (n = 244) of ATTR-CA at baseline. On multivariable logistic regression, higher Columbia score (OR: 1.48; 95% CI: 1.25-1.75) and higher left atrial volume index (LAVI) (OR: 1.05; 95% CI: 1.02-1.08) were associated with prevalent AF, whereas hereditary amyloid transthyretin (ATTRv) (OR: 0.19; 95% CI: 0.07-0.55) was protective (all P < 0.05). AF developed in 71 (41%) subjects without prior AF, over a median follow-up 2 years. On Cox regression, higher Columbia score (HR: 1.18; 95% CI: 1.01-1.38; P = 0.035) was associated with new onset AF, whereas CHARGE-AF and LAVI were not. ATTRv (HR: 0.44; 95% CI: 0.23-0.87; P = 0.017) and tafamidis (HR: 0.54; 95% CI: 0.30-0.95; P = 0.034) were protective. CONCLUSIONS: More than half of the ATTR-CA patients have AF, which was associated with wild-type amyloid transthyretin, greater Columbia stage, and increased LAVI. About half of the ATTR-CA individuals developed AF after 2 years, which was predicted by the Columbia score, but not the CHARGE-AF score. ATTRv and tafamidis were protective against incident AF.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York, New York, USA; Clinical Cardiovascular Research L…
- Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York, New York, USA.
Zitieren
APA
Chan, N., Brailovsky, Y., Teruya, S., Mirabal, A., Weinsaft, A. Y., De Los Santos, J., Guadalupe, S., Jimenez, M., Helmke, S., Cuomo, M., Smiley, D., Biviano, A., Dizon, J., Wan, E., Yarmohammadi, H., & Maurer, M. S. (2026). Atrial Fibrillation/Flutter in Transthyretin Cardiac Amyloidosis. JACC: Advances, 5(2), 102470. https://doi.org/10.1016/j.jacadv.2025.102470
Vancouver
Chan N, Brailovsky Y, Teruya S, Mirabal A, Weinsaft AY, De Los Santos J, et al. Atrial Fibrillation/Flutter in Transthyretin Cardiac Amyloidosis. JACC: Advances. 2026;5(2):102470. doi:10.1016/j.jacadv.2025.102470
BibTeX
@article{Chan2026,
author = {Chan, Nicholas and Brailovsky, Yevgeniy and Teruya, Sergio and Mirabal, Alfonsina and Weinsaft, Ariel Y and De Los Santos, Jeffeny and Guadalupe, Samantha and Jimenez, Massiel and Helmke, Stephen and Cuomo, Margaret and Smiley, Dia and Biviano, Angelo and Dizon, Jose and Wan, Elaine and Yarmohammadi, Hirad and Maurer, Mathew S},
title = {Atrial Fibrillation/Flutter in Transthyretin Cardiac Amyloidosis},
journal = {JACC: Advances},
year = {2026},
volume = {5},
number = {2},
pages = {102470},
doi = {10.1016/j.jacadv.2025.102470}
}
EUVIMED